Company intelligence / Profile preview

ISD Immunotech

Copenhagen, Denmark

Ownership: Private
Development stage: Other

Overview

ISD Immunotech is developing ISD-017, a peptide therapeutic that inhibits the STING pathway, showing strong preclinical efficacy in multiple SLE models including complete protection from kidney pathology[1][3].

Therapeutic areas: Immunology
Modalities: Peptide
Industry: Biotech

Partnerships

Biogen

Beyond the preview

Go deeper on ISD Immunotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISD Immunotech.

Explore the full profile